Under the terms of the deal, MDxHealth and QUT will evaluate and develop the test, which will evaluate abnormal DNA methylation changes.
DNA methylation changes at two markers can differentiate anal cancer and high-grade anal intraepithelial neoplasms from low-grade and benign samples.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.
The researchers concluded that each method has its own advantages and drawbacks depending on the sample being analyzed, cost restrictions, and the question.
Researchers have found that, in mice, good experiences can reverse the epigenetic effects of traumatic ones, as Scientific American reports.
The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.
The Singapore-based molecular diagnostics firm plans to use the funds for regulatory approvals and commercialization of its lead epigenetics-based test for breast cancer.
In Science this week: applying genome-editing technologies to crops, and more.
This month, GWG Life began sending out cheek swab kits to life insurance policy holders to analyze their saliva for epigenetic biomarkers developed at UCLA.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.
By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.
In Nature this week: a Danish reference genome, and more.